Kite Pharma

Lyell Immunopharma

This biopharmaceutical company develops chimeric antigen receptor T-cell therapies to treat patients with hematologic malignancies and solid tumours.

Juno Therapeutics

This biopharmaceutical company develops immunotherapies using genetically engineered cells to treat patients with various types of cancer.

CARGO Therapeutics

This biotechnology company develops engineered cell therapies to treat cancer patients with relapsed or resistant lymphoma.

Allogene Therapeutics

The company develops off-the-shelf allogeneic CAR T-cell therapies for patients with blood cancers, solid tumours and autoimmune diseases.

Enterome

This biopharmaceutical company develops microbiome-derived immunotherapies for patients with solid and liquid cancers, including non-Hodgkin lymphoma, and inflammatory diseases.

curocell

This company develops chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory blood cancers such as diffuse large B-cell lymphoma.

PACT Pharma

This biopharmaceutical company develops personalised and off-the-shelf gene-engineered T-cell therapies to treat patients with solid tumours.

Caribou Biosciences

This biopharmaceutical company develops genome-edited allogeneic cell therapies to treat patients with hematologic malignancies and other human diseases.